Bausch Health Cos Inc. (BHC) – What Are Researchers Saying About This Stock?

Bausch Health Cos Inc. (NYSE:BHC) has been given a consensus rating of “Hold” by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $8.00.

A number of equities analysts have recently issued reports on BHC shares. Zacks Research upgraded shares of Bausch Health Cos from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 21st. Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Royal Bank Of Canada restated a “sector perform” rating and set a $9.00 target price on shares of Bausch Health Cos in a research report on Thursday, October 8th. Weiss Ratings upgraded shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Finally, Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd.

Bausch Health Cos Stock Performance

NYSE:BHC opened at $6.30 on Tuesday. Bausch Health Cos has a 1 year low of $4.33 and a 1 year high of $8.00. The stock has a fifty day moving average price of $6.17 and a two-hundred day moving average price of $5.60. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -2.13 and a beta of 0.37.

Bausch Health Cos (NYSE:BHC) last issued its earnings results on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $0.96 by $0.30. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%. The company had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.59 billion. On average, analysts predict that Bausch Health Cos will post 4.35 EPS for the current year.

Insider Activity at Bausch Health Cos

In other news, insider Aimee Lenar sold 36,827 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the sale, the insider owned 334,853 shares of the company’s stock, valued at $2,354,016.59. The trade was a 9.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bausch Health Cos

Hedge funds have recently bought and sold shares of the company. Paulson & CO. Inc. acquired a new stake in Bausch Health Cos in the second quarter valued at $361,151,000. MFN Partners Management LP purchased a new position in shares of Bausch Health Cos in the second quarter valued at $29,580,000. Royal Bank of Canada increased its position in shares of Bausch Health Cos by 24.9% in the first quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after buying an additional 2,262,894 shares in the last quarter. Man Group plc purchased a new position in shares of Bausch Health Cos in the second quarter valued at $7,157,000. Finally, Bank of America Corp DE purchased a new position in shares of Bausch Health Cos in the second quarter valued at $2,816,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Cos Company Profile

Bausch Health Companies Inc is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, branded and generic pharmaceuticals, over-the-counter products and medical devices across a range of therapeutic areas.

Its business includes Salix Pharmaceuticals, which focuses on gastrointestinal treatments; Ortho Dermatologics, which develops prescription therapies for dermatological conditions; and Solta Medical, which provides energy-based medical and aesthetic devices.